Personalized Kampo Medicine Facilitated Both Cytotoxic T Lymphocyte Response and Clinical Benefits Induced by Personalized Peptide Vaccination for Advanced Esophageal Cancer.

Muroya, Daisuke; Yutani, Shigeru; Shichijo, Shigeki; Yamada, Akira; Sakamoto, Shinjiro; Naito, Masayasu; Okuda, Koji; Morita, Michi; Yamaguchi, Rin; Itoh, Kyogo

Muroya, Daisuke; Yutani, Shigeru; Shichijo, Shigeki; Yamada, Akira; Sakamoto, Shinjiro; Naito, Masayasu; Okuda, Koji; Morita, Michi; Yamaguchi, Rin; Itoh, Kyogo.

Afiliação

Muroya D; Department of Surgery, Kurume University School of Medicine, Kurume, Japan.
Yutani S; Cancer Vaccine Center, Kurume University, Kurume, Japan.
Shichijo S; Cancer Vaccine Center, Kurume University, Kurume, Japan.
Yamada A; Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Japan.
Sakamoto S; Cancer Vaccine Center, Kurume University, Kurume, Japan; Department of Molecular and Internal Medicine, Hiroshima University School of Medicine, Hiroshima, Japan.
Naito M; Cancer Vaccine Center, Kurume University, Kurume, Japan.
Okuda K; Department of Surgery, Kurume University School of Medicine, Kurume, Japan.
Morita M; Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Yamaguchi R; Division of Pathology, Medical Center of Kurume University, Kurume, Japan.
Itoh K; Cancer Vaccine Center, Kurume University, Kurume, Japan.

Evid Based Complement Alternat Med ; 2016: 5929525, 2016.

Article em En | MEDLINE | ID: mdl-27703488

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2016 Tipo de documento: Article